OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press2410.17650/1818-8346-2013-8-3-35-41HEMATOPOIETIC STEM CELL TRANSPLANTATIONТРАНСПЛАНТАЦИЯ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК У ПАЦИЕНТОВ С ГЕМОБЛАСТОЗАМИReduction in incidence of early fatal complications of high-dose chemotherapy with autologous hematopoietic stem cell transplantation in Hodgkin lymphoma patientsСнижение частоты ранних фатальных осложнений высокодозной химиотерапии с транспл антацией аутологичных клеток-предшественников гемопоэза при лимфоме ХоджкинаZhukovN. V.ЖуковН. В.
Russian Federation
zhukov.nikolay@rambler.ruUssA. L.УссА. Л.
Russian Federation
MilanovichN. F.МилановичН. Ф.
Russian Federation
PtushkinV. V.ПтушкинВ. В.
Russian Federation
AfanasyevB. V.АфанасьевБ. В.
Russian Federation
MikhaylovaN. B.МихайловаН. Б.
Russian Federation
LarionovaV. B.ЛарионоваВ. Б.
Russian Federation
DeminaE. A.ДеминаЕ. А.
Russian Federation
KaramaneshtE. E.КараманештЕ. Е.
Russian Federation
TyurinaN. G.ТюринаН. Г.
Russian Federation
PavlovaO. A.ПавловаО. А.
Russian Federation
RumyantsevA. G.РумянцевА. Г.
Russian Federation
KaprinA. D.КапринА. Д.
Russian Federation
P.A. Gertsen Moscow Research Institute of Oncology, Ministry of Health of Russia Dmitriy Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of RussiaФГБУ «Московский научно-исследовательский онкологический институт им. П.А. Герцена» Минздрава России ФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава РоссииNational Center of Hematology and Bone Marrow TransplantationРеспубликанский центр гематологии и трансплантации костного мозгаDmitriy Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of RussiaФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава РоссииRaisa Gorbacheva Memorial Institute of Children Hematology and Transplantation, First Saint Petersburg Pavlov State Medical University, Ministry of Health of RussiaИнститут детской гематологии и трансплантологии им. Р.М. Горбачевой ГБОУ ВПО ПСпбГМУ им. акад. И.П. Павлова Минздрава РоссииN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesФГБУ «Российский онкологический научный центр им. Н.Н. Блохина РАМН»Kiev Center of Bone Marrow TransplantationКиевский центр трансплантации костного мозгаP.A. Gertsen Moscow Research Institute of Oncology, Ministry of Health of RussiaФГБУ «Московский научно-исследовательский онкологический институт им. П.А. Герцена» Минздрава России2108201383354121072014210720142013https://oncohematology.abvpress.ru/ongm/article/view/24

Traditionally, the concern of fatal complication is a major obstacle to transfer patients with unfavorable course of Hodgkin’s lymphoma tonational transplantation centers. Early mortality after high-dose chemotherapy with autologous hematopoietic stem cell transplantation(HSCT) in the Russia, Ukraine and Belarus was assessed in this retrospective multicenter study.

Patients and methods. The study included 372 patients with unfavorable course of Hodgkin’s lymphoma received HSCT between 01.1990and 06.2013: 35.5 % patients with primary resistance, 30.6 % with early relapse, 33.1 % with late relapse and 0.8 % during consolidation offirst complete remission.

Results. During first 100 days after HSCT died 14 (3.8 %) patients, during first year – 31 (8.4 %) patients. During the study period a significant decrease in the 100-day and 1-year mortality rate was observed (p < 0.0001 for both). Among patients received HSCT in 1990–1995, 1996–2000, 2001–2005 and 2006–2013 the 100-day mortality was 19.4 %, 6.3 %, 1.1 % and 0.6 %, respectively. 1-year mortality for the same intervals was 32.3 %, 14.7 %, 4.5 % and 1.9 %, respectively.

Conclusions. Currently HSCT in patients with unfavorable course of Hodgkin's lymphoma in national transplant centers, accompanied by an extremely low risk of fatal toxicity.

Hodgkin lymphomahigh-dose chemotherapyhematopoietic stem cell transplantationtoxicityлимфома Ходжкинавысокодозная химиотерапиятрансплантация клеток-предшественников гемопоэзатоксичность1. Linch D., Winfield D., Goldstone A. et al. Dose intensification with autologous bonemarrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051.Linch D., Winfield D., Goldstone A. et al. Dose intensification with autologous bonemarrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051.2. Schmitz N., Sextro M., Pfistner B. HDR-1: high-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD): final results of a randomized GHSG and EBMT trial (HD-R1). Proc Am Soc Clin Oncol 1999;18(Suppl 5):18.Schmitz N., Sextro M., Pfistner B. HDR-1: high-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD): final results of a randomized GHSG and EBMT trial (HD-R1). Proc Am Soc Clin Oncol 1999;18(Suppl 5):18.3. Sweetenham J.W., Carella A.M., Taghipour G. High-dose therapy and autologous stem cell transplantation for adult patients with Hodgkin's disease who fail to enter remission after induction chemotherapy: results in 175 patients reported to the EBMT. J Clin Oncol 1999;17:3101.Sweetenham J.W., Carella A.M., Taghipour G. High-dose therapy and autologous stem cell transplantation for adult patients with Hodgkin's disease who fail to enter remission after induction chemotherapy: results in 175 patients reported to the EBMT. J Clin Oncol 1999;17:3101.4. Lazarus H., Rowlings P., Zhang M. et al. Autotransplants for Hodgkin's disease in patients never achieving remission:a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999;17:534.Lazarus H., Rowlings P., Zhang M. et al. Autotransplants for Hodgkin's disease in patients never achieving remission:a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999;17:534.5. Goldstone A.H., McMillan A.K. The place of high-dose therapy with haemopoietic stem cell transplantation in relapsed and refractory Hodgkin's disease. Ann Oncol 1993; 4 Suppl 1:21–7.Goldstone A.H., McMillan A.K. The place of high-dose therapy with haemopoietic stem cell transplantation in relapsed and refractory Hodgkin's disease. Ann Oncol 1993; 4 Suppl 1:21–7.6. Horning S.J., Chao N.J., Negrin R.S. et al. High-dose therapy and autologous hematopoietic rogenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 1997;89:801–13.Horning S.J., Chao N.J., Negrin R.S. et al. High-dose therapy and autologous hematopoietic rogenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 1997;89:801–13.7. Ptushkin V.V., Afanasyev B.V., Zhukov N.V. et al. Efficacy and safety of high-dose chemotherapy with autologous hematopoietic stem cell rescue for relapsed/refractory Hodgkin‘s lymphoma patients in former USSR countries. Retrospective analysis of data from four transplantation centers in Belarus, Russia and the Ukraine. Cellular Therapy and Transplantation 2008;1(1):43–7.Ptushkin V.V., Afanasyev B.V., Zhukov N.V. et al. Efficacy and safety of high-dose chemotherapy with autologous hematopoietic stem cell rescue for relapsed/refractory Hodgkin‘s lymphoma patients in former USSR countries. Retrospective analysis of data from four transplantation centers in Belarus, Russia and the Ukraine. Cellular Therapy and Transplantation 2008;1(1):43–7.8. Linch D.C., Milligan D.W., Winfield D.A. et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Brit J Haematol 1997;99(4):933–8.Linch D.C., Milligan D.W., Winfield D.A. et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Brit J Haematol 1997;99(4):933–8.9. Majolino I., Pearce R., Taghipour G., Goldstone A.H. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non- Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data.Majolino I., Pearce R., Taghipour G., Goldstone A.H. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non- Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data.Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 1997;15(2):509–17.10. Sureda A., Constans M., Iriondo A. et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005;16(4):625–33.Sureda A., Constans M., Iriondo A. et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005;16(4):625–33.